= 1.79 ± 0.05 µM), supporting its targeted anti-angiogenic mechanism. Flow cytometry analysis showed that 7e induced G0/G1 cell cycle arrest and markedly increased apoptotic cell populations. This was further confirmed by upregulation of Bax, Caspase-3, and Caspase-8, alongside downregulation of Bcl-2, indicating activation of both intrinsic and extrinsic apoptotic pathways. Interestingly, 7e inhibited cancer cell migration, suggesting a potential anti-angiogenetic effect. Density functional theory (DFT) calculations revealed that 7e possesses a conjugated electronic system with a suitable frontier orbital distribution, moderate HOMO-LUMO gap, and a favorable electrostatic potential for receptor interaction. Molecular docking and dynamics simulations demonstrated stable binding of 7e within the VEGFR-2 active site, supported by consistent RMSD, hydrogen bonding, and compact structural behavior. MM-GBSA calculations confirmed favorable binding free energy, while per-residue decomposition and protein-ligand interaction fingerprint analysis identified key stabilizing interactions. Essential dynamics and free energy landscape mapping further confirmed a stable and energetically favorable conformational state. ADMET and toxicity predictions indicated acceptable pharmacokinetic properties, low mutagenic risk, and an overall favorable safety profile. Collectively, these findings identify compound 7e as a promising VEGFR-2-targeted anticancer lead with strong enzymatic inhibition, potent cytotoxicity, and a well-supported mechanistic profile integrating experimental and computational evidence.
Frontiers in Cellular and Infection Microbiology · مجلد 16
Correction on: Othman G, A. Badawy A, Hamed Al-Serwi R, El Sayed Zaki M, Tharwat Abou Elkhier N, Alkassaby NM and Saleh Ismail M (2026) Molecular epidemiology of carbapenemaseproducing gram-negative bacilli in diabetic foot infections: association with glycemic control. Front. Cell. Infect. Microbiol. 16:1847743. doi: 10.3389/fcimb.2026.1847743.Grant/funding/project number incorrect An incorrect number was provided for the Deanship of Scientific Research at Northern Border University, Arar, Saudi Arabia. The correct number is NBU-FFR-2026-52-03The original version of this article has been updated.
Background Early prophylactic low-dose hydrocortisone has been proposed to reduce inflammation and to compensate for relative adrenal insufficiency in extremely preterm infants. Its overall balance of benefit and risk remains uncertain. Objective To evaluate whether hydrocortisone initiated within the first 24–48 h after birth reduces bronchopulmonary dysplasia (BPD) and mortality in infants born before 30 weeks' gestation. Methods This systematic review and meta-analysis followed PRISMA 2020 guidance and was registered in PROSPERO. PubMed, Cochrane CENTRAL, Scopus, and Web of Science were searched from inception to May 2026. Eligible studies enrolled infants born before 30 weeks' gestation who received early prophylactic systemic hydrocortisone at a low dose. Low dose was defined as a starting dose of no more than 2.0 mg/kg/day, begun within 24–48 h of birth. The comparator was placebo or no hydrocortisone. Randomized and quasi-randomized trials, their follow-up reports, and comparative observational studies were eligible. Random-effects meta-analyses were performed using risk ratios (RRs) or mean differences with 95% confidence intervals (CIs). Results Fourteen studies with 3,416 infants were included. Early hydrocortisone did not significantly improve survival without BPD at 36 weeks' postmenstrual age (RR: 1.07, 95% CI: 0.97–1.19, p = 0.18). It also did not significantly reduce BPD at 36 weeks (RR: 0.94, 95% CI: 0.85–1.04, p = 0.25) or mortality before discharge (RR: 1.07, 95% CI: 0.77–1.49, p = 0.69). The duration of respiratory support and the need for oxygen at discharge were similar between groups. Subgroup analyses suggested a possible benefit in infants exposed to chorioamnionitis and in those born before 26 weeks, but these findings were exploratory. Hydrocortisone increased the risk of late-onset sepsis (RR: 1.19, 95% CI: 1.05–1.35, p = 0.01). Gastrointestinal perforation, necrotizing enterocolitis, major neonatal morbidities, and the available neurodevelopmental outcomes did not differ significantly between groups. Conclusion Current evidence does not support the routine use of early prophylactic hydrocortisone in all extremely preterm infants. Adequately powered trials and individual patient data analyses are needed to identify the subgroups most likely to benefit and to clarify long-term safety. Systematic Review Registration https://www.crd.york.ac.uk/prospero/view/CRD420261402317 , PROSPERO CRD420261402317.
Background Chronic obstructive pulmonary disease (COPD) with exacerbations often triggered by infections. Bacterial lysates have been investigated as interventions to reduce the exacerbations of COPD. Methods We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) evaluating bacterial lysates (BLs) in adults with chronic obstructive pulmonary disease (COPD). PubMed, EMBASE, CENTRAL, Web of Science, Google Scholar, ICTRP, and ClinicalTrials.gov were searched. In adults with COPD that compared bacterial lysates with placebo or conventional COPD therapy. Primary outcomes were the effect of BLs on exacerbations and duration. Secondary outcomes were hospitalisation risk, the mean number of exacerbations per participant during trial follow up, symptom scores for dyspnoea, sputum, cough, and adverse events. We used random-effects meta-analysis, assessed risk of bias with Cochrane RoB 2, graded certainty with GRADE. Results Fifteen RCTs were included. The pooled risk ratio (RR) for exacerbation in patients with COPD treated with BLs vs. control was 0.83 (95% CI 0.74–0.93; P = 0.0009). The mean difference (MD) for exacerbation duration showed no statistical significant reduction −9.26 Days (95% CI −19.56 to 1.03; P = 0.08). Mean number of exacerbations (MD) −0.19 (95% CI −0.30 to −0.08; P = 0.0009). Hospitalisation RR was 0.52 (95% CI 0.35–0.78; P = 0.001).Symptom outcomes were dyspnoea standardised mean difference (SMD) −0.42 (95% CI −0.75 to −0.10; P = 0.01), cough (SMD) −0.37 (95% CI −0.63 to −0.11; P = 0.006), while sputum production showed no significant change (SMD) −0.20 (95% CI −0.65 to 0.25; P = 0.39), The RR for adverse events was 0.95 (95% CI 0.86–1.04; P = 0.27). Conclusion Bacterial lysates may be associated with lower COPD exacerbation and hospitalisation risk, with small numerical improvements in dyspnoea, cough, sputum production showed no significant improvement; effects varied by formulation, these findings require confirmation in formulation specific trials. Systematic Review registration https://www.crd.york.ac.uk/PROSPERO/view/CRD42024570783 , PROSPERO CRD42024570783.
Tavapadon is an oral, once-daily, non-catechol partial agonist selective for the D1 and D5 dopamine receptors and represents a mechanistically distinct option currently under clinical investigation for Parkinson disease (PD). This narrative review critically evaluates the biological rationale for D1/D5 receptor targeting, the pharmacological and preclinical development of tavapadon, and the accumulating phase 1–3 clinical evidence for its use as monotherapy in early PD and as adjunctive therapy in patients with motor fluctuations, while highlighting remaining evidence gaps and methodological limitations. A non-systematic literature search of PubMed/MEDLINE, Embase, ClinicalTrials.gov , and Scopus (through May 2026) was performed to identify representative and pivotal randomized controlled trials, pharmacokinetic/pharmacodynamic studies, and mechanistic preclinical investigations relevant to tavapadon and D1/D5 receptor agonism; this narrative approach was not intended to be exhaustive or fully reproducible in the manner of a systematic review. Mechanistically, selective stimulation of the direct striatal pathway together with submaximal intrinsic efficacy at the D1 receptor has been proposed, as a mechanistic hypothesis rather than a demonstrated clinical mechanism, to preserve antiparkinsonian benefit while limiting the receptor-signaling intensity implicated in levodopa-induced dyskinesia. In the phase 2 PARKWAY-II study and the now fully published phase 3 TEMPO-1 and TEMPO-2 trials, fixed- and flexible-dose tavapadon produced clinically meaningful improvements in MDS-UPDRS motor scores compared with placebo in early PD, and in the phase 3 TEMPO-3 trial, adjunctive tavapadon significantly increased daily good ON time and reduced OFF time in levodopa-treated patients with motor fluctuations; efficacy in all trials has been demonstrated only against placebo, with no head-to-head data against levodopa or other dopamine agonists. Adverse events were more frequent with tavapadon than placebo (approximately 72–76% versus 55% across TEMPO-2 and TEMPO-3), with nausea, headache, and dizziness the most common; no excess signal of impulse-control disorders relative to placebo was detected over the available 26–27-week controlled treatment period, and no clinically significant QTc prolongation was observed. The 58-week open-label TEMPO-4 extension, now reported in a peer-reviewed AAN abstract publication in Neurology alongside earlier interim conference data, suggests sustained benefit and a stable long-term levodopa requirement, but lacks a randomized control and cannot yet establish long-term safety superiority over existing agents. Tavapadon is a mechanistically novel candidate with preliminary evidence of efficacy; its ultimate clinical utility will depend on head-to-head trials and long-term safety data.
Frontiers in Cellular and Infection Microbiology · مجلد 16 · 1847743-1847743
Background Carbapenem-resistant Gram-negative bacilli are an increasing threat in diabetic foot ulcer (DFU) infections, limiting therapeutic options and worsening outcomes. However, data linking specific carbapenemase genes to clinical and metabolic factors remain limited. Objectives To isolate Gram-negative bacilli from deep tissue biopsies of DFUs, determine carbapenem susceptibility by minimum inhibitory concentration (MIC) testing, detect major carbapenemase genes by multiplex qPCR, and evaluate their association with glycemic control and Wagner grade. Methods This cross-sectional study included 150 patients with infected DFUs. Isolates recovered from tissue and other specimens were identified by standard microbiological methods, and carbapenem susceptibility was assessed by MIC testing. Multiplex qPCR was used to detect bla KPC, bla NDM, bla OXA-48, bla VIM, and bla IMP, and associations between resistance determinants and clinical variables were analyzed statistically. Results The mean patient age was 56.4 ± 9.8 years, with a male predominance (61.3%), and high-grade ulcers (Wagner III–V) were present in 54.7% of patients. Klebsiella pneumoniae predominated (60.0%), followed by Pseudomonas aeruginosa and Escherichia coli (each 14.7%). Resistance to meropenem and imipenem was high (77.3% and 75.3%, respectively), and carbapenemase production was detected in 84.0% of isolates. bla KPC (28.0%) and bla NDM (24.0%) were the most prevalent genes and were significantly associated with phenotypic carbapenemase production (P = 0.002 and P = 0.006, respectively). Carbapenemase producers showed significantly higher fasting glucose and HbA1c levels than non-producers (P < 0.001), with no significant association observed for Wagner grade (P = 0.570). Conclusions DFUs showed a high burden of carbapenemase-producing Gram-negative bacilli, driven mainly by bla KPC and bla NDM. Poor glycemic control was strongly associated with these resistant infections, underscoring the need for integrated metabolic management, molecular surveillance, and antimicrobial stewardship. These findings position glycemic control as a modifiable driver of antimicrobial resistance in DFUs.
Frontiers in Pharmacology · مجلد 17 · 1847011-1847011
Background Endothelial dysfunction driven by intermittent hypoxia (IH)-induced oxidative stress, nitric oxide depletion, and adhesion molecule upregulation underlies obstructive sleep apnea (OSA)-related cardiovascular complications. Vitamin D deficiency, which frequently coexists with OSA, may further amplify this endothelial injury through impaired endothelial nitric oxide synthase (eNOS) regulation and heightened renin-angiotensin-aldosterone system (RAAS) activity; however, the dose-dependent therapeutic potential of vitamin D3 on combined endothelial and renal outcomes in an IH model remains uncharacterized. Methods Fifty-six adult male Sprague-Dawley rats were allocated to seven groups: control, vitamin D-deficient (VDD), VDD with severe IH (SIH-VDD), and four supplementation subgroups receiving high-dose (37.5 μg/kg/day) or low-dose (25 μg/kg/day) cholecalciferol under severe or moderate IH for 14 days. Serum E-selectin, ICAM-1, ET-1, NO, and PCSK9 were quantified by ELISA. Renal histopathology was assessed on H&E sections by a blinded pathologist. Data were analyzed by one-way MANOVA, univariate ANOVA, and LSD post hoc tests (p < 0.05). Results The SIH-VDD group showed the most severe endothelial activation: peak E-selectin (4.92 ± 0.90 ng/mL), ICAM-1 (201.50 ± 21.55 ng/mL), ET-1 (5.31 ± 0.81 pg/mL), and PCSK9 (213.50 ± 14.71 ng/mL), with the lowest NO (14.88 ± 2.16 μmol/L; all p < 0.001 vs. control). High-dose supplementation produced substantial recovery across all markers; PCSK9 normalized to near-control (162.50 ng/mL) under severe IH. Low-dose supplementation yielded incomplete normalization. Renal histopathology revealed mild interstitial lymphocytic infiltration in IH-exposed groups, with proximal tubular vacuolisation exclusively in the SIH-VDD group and entirely absent in all supplemented groups. Glomerular architecture remained preserved throughout. Conclusion Vitamin D deficiency combined with IH upregulates endothelial dysfunction markers and induces renal tubular injury in an experimental OSA model. High-dose vitamin D 3 attenuates these changes dose- and severity-dependently, supporting its role as a pharmacological adjunct for OSA-associated endothelial and renal complications.
Introduction: Vision impairment caused by retinal diseases stands out as one of the significant sources of irreversible blindness, highlighting the importance of developing robust automated screening tools to detect eye diseases at an early stage. Despite the promising results of recent deep learning approaches to the automatic classification of retinal images, most existing solutions focus on image-based representations and do not consider the importance of vascular topology. To overcome the limitations, this study proposes VG-RETFound - a hybrid framework based on a retinal foundation model and graph-based vascular-topology modeling that can be used to classify multiple retinal categories and detect vision impairment. Methods: The authors use RETFound-a retinal foundation model-pretrained on a vast number of retinal images, as well as the Graph Attention Network (GAT), to learn vascular topology features by representing retinal vessels as graphs. The presented approach employs a cross-modal multi-head attention fusion method to integrate features from both modalities in real time. To evaluate the efficiency of VG-RETFound, experiments were conducted using the RFMiD and ODIR-5 K datasets for model training and testing across six retinal categories: Normal, Diabetic Retinopathy, Pathological Myopia, Age-related Macular Degeneration, Hypertensive Retinopathy, and Other Retinal Diseases. Results: The accuracy of 96.39%, F1-score of 95.84%, MCC of 94.87%, and Kappa of 94.71% were attained on an internal test dataset, while cross-dataset external validation on the BRSET dataset revealed accuracy of 94.81%, F1-score of 94.25%, MCC of 93.09%, and Kappa of 92.94%. Discussion: These findings demonstrate that integrating retinal foundation models with anatomically informed vessel-topology learning significantly improves classification accuracy, interpretability, and generalization, highlighting the potential of VG-RETFound as a tool for large-scale vision impairment. screening and retinal disease diagnosis.
Frontiers in Pharmacology · مجلد 17 · 1826774-1826774
Introduction: Myelotoxicity is a common adverse effect of vincristine and other chemotherapeutic drugs. Hesperetin is a bioactive flavanone with anti-inflammatory activity. This study was planned to examine the hesperetin protecting effect against vincristine induced myelosuppression and splenic inflammation in mice and test whether this effect is mediated through the suppression of Toll-like receptor 4 (TLR4)/myeloid differentiation primary response-88 (MYD88)/nuclear factor-kappa B (NF-κB) signaling pathways. Methods: Bioinformatics tools were used to establish the rationale of the study and molecular docking defined the potential binding of hesperetin to TLR4. Mice were allocated into different experimental groups: Group 1: was the saline mice, Group 2; mice were injected with vincristine (0.1 mg/kg, i. p) for 5 days per week, Group 3; mice received vincristine (as in Group 2) plus hesperetin (100 mg/kg, p. o.) and Group 4; mice received hesperetin (100 mg/kg, p. o.) only; the experiment continued for 2 weeks. Results: 9/L in the saline group, p less than 0.05) and bone marrow hypocellularity (dropped to ∼30-40% compared to 95%-100% in the saline group). The spleens showed white pulp lymphoid depletion, red pulp mild hypocellularity, greater immunostaining for MYD88, and greater content for TLR4, NF-κB, MYD88, TNF-α and IL-1β proteins. Results of molecular docking showed that hesperetin is an interesting complementarity with the TLR4/MD2 interface which was a good rationale for the experimental validation. The mouse experiment showed that hesperetin prevented the decrease hematological parameters, enhanced the bone marrow cellularity to 80%-90%, and the splenic architecture. Hesperetin further inhibited the increases in the target proteins (TLR4, NF-κB, MYD88, TNF-α and IL-1β) significantly. Discussion: The present data documents the novel role of hesperetin in mitigating myelotoxicity of vincristine through modulation of TLR4/MYD88/NF-κB signaling and a direct binding to TLR4 was proposed by molecular docking. This highlights possible usefulness of this combination after adequate clinical studies.
Frontiers in Public Health · مجلد 14 · 1866985-1866985
Background: Irritable bowel syndrome (IBS) is a chronic functional bowel disease and a common cause of gastroenterological referrals. This cross-sectional survey estimated the prevalence of Rome IV-defined IBS symptoms among adults residing in Saudi Arabia and examined their associations with sociodemographic characteristics, and self-reported symptoms of depression, anxiety, and stress. Methodology: A cross-sectional online survey was conducted from August 2024 to March 2025 among adults aged 18 years or above residing in the five regions of Saudi Arabia. It was coordinated by the Faculty of Medicine, King Abdulaziz University, Rabigh, Saudi Arabia. Participants were recruited through electronic platforms, and data were collected using a self-administered questionnaire that included sociodemographic variables, Rome IV symptom questions with the Bristol Stool Form Scale, and Arabic version of the Depression, Anxiety, and Stress Scale-21 (DASS-21). Results: A total of 1,553 participants completed the survey. Overall, 373 participants (24%) met the Rome IV symptom-based criteria for IBS. Participants with IBS symptoms had significantly higher mean DASS-21 depression, anxiety, and stress scores than participants without IBS symptoms. IBS symptoms were more common among participants aged 25-50 years, married, living in the Eastern region, and individuals with master's degrees. Among participants who met the Rome IV criteria, all reported recurrent abdominal pain at least once weekly over the past 3 months, and 255 (68.4%) reported that their abdominal pain was always related to time of defecation. A large number of participants (322, 86.3%) who met the Rome IV symptom-based criteria for IBS reported a moderate impact of IBS on their lifestyle. Based on the Bristol Stool Form Scale, 166 participants (44.5%) were classified as IBS-D (diarrhea), 129 (34.6%) as IBS-C (constipation), and 78 (20.9%) as IBS-M (mixed). In multivariable logistic regression, age, education level, and depression, anxiety, and stress symptom categories were statistically associated with IBS symptoms. Conclusion: In this online cross-sectional survey, 24% of respondents met symptom-based Rome IV criteria for IBS. IBS symptoms were associated with higher self-reported depression, anxiety, and stress scores and selected sociodemographic factors. Longitudinal and clinical studies are needed to clarify temporality and inform integrated gastrointestinal and psychological care.
irritable bowel syndromeRome IV criteriadepressionanxiety
Frontiers in Pharmacology · مجلد 17 · 1860075-1860075
Background/objectives: Liver fibrosis is the consequence of the wound-healing response of the liver to frequent injury. Calycosin is a flavonoid, which has been documented for its hepatoprotective properties. The aim of this study was to evaluate the hepatoprotective action of calycosin in a model of ethanol-induced liver injury (EILI) in rats. For mechanistic insights, we aimed to measure tumor necrosis factor-α (TNF-α), nuclear factor-κB (NF-κB), and hypoxia-inducible factor-1 alpha (HIF-1α) protein levels in liver samples and evaluate the ability of calycosin to bind these pathologic molecules. Methods: Network pharmacology and molecular docking were performed for discovering the interacting target proteins. Forty male rats were assigned into five groups: 1) the vehicle, 2) the calycosin per se group, 3) the EILI control group, and 4) and 5) the EILI + calycosin (5 or 10 mg/kg) groups. The liver homogenates were used for ELISA measurement of TNF-α, NF-κB, and HIF-1α. Furthermore, liver specimens were used for histopathological and ultrastructural investigations. Results: The network pharmacology study confirmed the role of TNF-α/NF-κB/HIF-1α signaling in EILI, and molecular docking explored the possible interaction between calycosin and these three molecules (docking score = -7.6, -7, and -7.6 kcal/mol). The rat study showed that calycosin was able to attenuate histopathological and ultrastructural changes in rat livers, reduce collagen accumulation, and prevent the increases shown in liver enzyme activities (2.17-fold for ALT and 2.26-fold for AST). Conclusion: studies confirmed the hepatoprotective effect of calycosin against the EILI rat model and provided a mechanistic insight through TNF-α/NF-κB/HIF-1α signaling. Further studies are warranted to fully explore the protective mechanism of calycosin in EILI.
Background Irinotecan is a potent chemotherapeutic agent used as a neoadjuvant in colorectal cancer liver metastasis and significantly enhances five-year survival rates. Recently, irinotecan-associated hepatotoxicity was a significant concern. Given the limited study in this area, we aimed to identify risk factors associated with irinotecan-induced hepatotoxicity. Methods This is a retrospective cohort study at King Saud University Medical City in Riyadh. The study encompassed all adult cancer patients who received irinotecan treatment between Jun 2017 and December 2023. The clinical records of patients were reviewed to assess factors associated with hepatotoxicity. Time-to-event analyses were performed using time-varying exposure. Results The study includes 229 adult cancer patients who received irinotecan-based treatment. Median age was 58 years, and colorectal cancer was the most diagnosed type of cancer (68.6%). Over a median follow-up of 103 days, the incidence of hepatotoxicity was 19.2% (n=44). In the adjusted analysis, higher baseline AST was associated with an increased hazard of hepatotoxicity (HR = 1.01; 95% CI: 1.01–1.02; p = 0.001). Cumulative irinotecan dose showed an inverse association with hepatotoxicity, with lower hazards observed in the medium cumulative dose group (HR = 0.36, 95% CI: 0.14–0.91, p = 0.031) and high cumulative dose group (HR = 0.06, 95% CI: 0.01–0.48, p = 0.008) compared with the low cumulative dose group. Conclusion In summary, an inverse association was observed between cumulative irinotecan dose and hepatotoxicity. A higher baseline AST was also associated with hepatotoxicity, warranting careful assessment of pretreatment liver enzymes and closer monitoring during the early treatment period. Further studies are needed to validate these findings and investigate additional predictors of irinotecan-related hepatotoxicity.
Frontiers in Pharmacology · مجلد 17 · 1822157-1822157
Background: The worldwide burden of metabolic dysfunction-associated steatotic liver disease (MASLD) is rising sharply, powered by high prevalence of obesity and its associated metabolic insults. Though urgent, definitive treatment is not yet available. Empagliflozin, a sodium glucose co-transporter inhibitor has been suggested in both human and animal studies to have diverse beneficial effects in MASLD by anti-inflammation and anti-oxidative stress effects, but many of the underlying mechanisms remain unexplained. The main aim of this systematic review and meta-analysis was to evaluate the effects of empagliflozin's in preclinical animal studies trying to view new horizons for future treatment of MASLD. Methods: we searched the related animal preclinical studies in databases including Scopus, Web of Science, Cochrane library, Wily online library and PubMed. The research team screened the literature and extracted data; any discrepancies were resolved by the research team leader through discussion. The quality of research methods was assessed by SYRCLE (systematic review center for laboratory animal experimentation) risk of bias tool. The meta-analysis was guided by the Cochrane Handbook; statistical analyses were conducted via RevMan 5.4 offline version and Comprehensive Met analysis V3 software. Results: Our meta-analysis included 17 studies, involving 584 animals. In comparison with the model group, empagliflozin significantly reduced steatosis markers including hepatic burden of lipids, including triglycerides and cholesterol, NAFLD Activity Score (NAS) and total serum cholesterol (TC). It also significantly reduced hepatic fibrosis markers including fibrosis grade, transforming growth factor-β (TGF-β) and collagen type I alpha 1 chain) COL1A1). Beyond its anti-steatofibrotic effects, empagliflozin significantly downregulated hepatic expression of inflammatory and oxidative markers including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) and malondialdehyde (MDA). Moreover, empagliflozin significantly improved glycemic indices including Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), serum insulin, and fasting blood sugar (FBS). Conclusion: Empagliflozin significantly protected the liver against steatosis and fibrosis by mitigating hepatic inflammation, oxidative stress and insulin resistance.
Background and objectives Oocyte freezing can be performed for up to ten years, with regulations regarding storage duration and age limits varying by country, including a maximum age of up to 50 years in some regions. The standard method for oocyte retrieval is transvaginal ultrasound; however, it is not suitable for patients with an intact hymen, particularly in regions with cultural and religious considerations, such as the Middle East. For these patients, transrectal ultrasound-assisted retrieval represents a safe alternative. This study evaluates transrectal oocyte retrieval and compares it with conventional ultrasound-guided transvaginal aspiration. Materials and methods This prospective observational study involved 120 patients undergoing oocyte cryopreservation, divided into two groups: transrectal oocyte retrieval (TROR) for patients with intact hymens, and transvaginal oocyte retrieval (TVOR) for those without. The study compared follicle and oocyte retrieval counts between these groups, using regression analyses to evaluate the impact of variables such as age, body mass index (BMI), anti-Müllerian hormone (AMH), anesthesia duration, procedural time, and peak estradiol (E2) on the triggering day. Results Number of oocytes correlated negatively with age in TROR and TVOR groups ( r = −0.10, −0.55, P = 0.22, P < 0.001, respectively). It also correlated negatively with BMI in both groups ( r = −0.20, −0.12, P = 0.03, P = 0.19, respectively). Number of oocytes showed a significant strong positive correlation with AMH level, anesthesia time, surgery time, peak E2 on triggering day, and number of follicles in the TROR group ( r = 0.80, 0.56, 0.55, 0.81, 0.69, P < 0.001). Similarly, it showed significant moderate correlation with AMH ( r = 0.40, P < 0.01) and strong correlation with anesthesia time, surgery time, peak E2 on triggering day, and number of follicles in the TVOR group ( r = 0.73, 0.74, 0.80, 0.85, P < 0.001). Conclusion Transvaginal oocyte collection is the standard and easiest method for oocyte retrieval. However, for patients with an intact hymen particularly in regions with cultural and religious considerations, trans-rectal oocyte collection is also regarded as a safe and simple alternative.
Introduction: Developmental dyslexia refers to a common neurodevelopmental disorder, which impairs the accuracy and fluency of reading, and early identification is vital for initiating timely intervention. Nonetheless, the traditional methods of formal assessment are time- and resource-intensive, which limits their scalability. Machine-learning approaches and eye-tracking technologies provide objective, data-driven solutions for dyslexia screening. This research integrates current evidence on eye-movement-based and emerging multimodal computational methods for dyslexia screening, risk identification, and algorithmic classification during reading tasks. Methods: PubMed, Scopus, Web of Science, and CINAHL were searched systematically to identify studies published between January 2015 and March 2026. Eligible studies included analysis of eye-movement obtained via eye tracking or electrooculography (EOG), with or without predictive modeling. Methodological quality was assessed using JBI, PROBAST, ROBINS-I, and COSMIN tools. Results: = 2). The sample sizes ranged from small experimental cohorts (<20 participants) to larger datasets (>300 participants). In the literature, dyslexic readers were consistently found to exhibit longer fixation durations, increased regression behavior and reduced saccadic efficiency. Machine-learning algorithms using fixation, saccade, scan path, and signal-based features demonstrated classification accuracies ranging from approximately 80 to 95% with some studies reporting values approaching 99% under specific experimental conditions. Discussion: Nevertheless, there was a significant heterogeneity in datasets, feature extraction methods, outcome definitions and validation schemes. Notably, numerous studies used proxy diagnostic labels, small or internally derived datasets, and internal cross-validation, which introduces the risk of overfitting and performance inflation. Explicit multimodal or multi-source modeling was identified in three of 23 studies involving combinations of gaze data with demographic, cognitive, linguistic, VR-bed, text-derived, saliency-map, or CNN-based features. Two additional studies used EOG as an alternative eye-movement signal modality rather than true multi-source fusion. Therefore, the evidence base remains dominated by eye-movement and gaze-derived approaches, while multimodal evidence should be interpreted as emerging and exploratory. Altogether, eye-movement based computational systems are a promising, non-invasive method for scalable dyslexia screening. Systematic review registration: PROSPERO, identifier (RD42061332527).